Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease
Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease
复制标题
DOI：
10.1097/fjc.0b013e3180325af3
复制
发表时间：
2007-04-01
影响因子：
3
通讯作者：
Sueda, Taijiro
中科院分区：
文献类型：
--
作者：
Miyazaki, Masanori;Higashi, Yukihito;Sueda, Taijiro
外周动脉疾病（PAD）是动脉粥样硬化的主要表现之一。PAD与内皮功能障碍相关。盐酸沙格雷酯是一种选择性5-HT 2A拮抗剂，已被广泛用作治疗PAD的抗血小板药物。没有关于PAD患者开始沙格雷酯治疗后内皮功能是否改善的信息。本研究的目的是评价沙格雷酯对PAD患者内皮功能的影响。我们将PAD患者分为两组：沙格雷酯组，10例，口服沙格雷酯100 mg，每日3次，共12周;对照组，11例，继续常规治疗。用应变式容积描记法测定前臂血流（FBF）和腿部血流（LBF）对反应性充血（RH）和舌下含服硝酸甘油（NTG）的反应。沙格雷酯给药12周后，RE期间的FBF和LBF反应分别从每100 mL组织13.2 +/- 1.7至18.1 +/- 2.2 mL/min（P < 0.01）和从每100 mL组织8.2 +/- 0.9至14.2 +/- 2.1 mL/min（P < 0.05）显著增加。Sarpogrelate诱导的FBF和LBF对RH反应的增强在24周时得以维持。对照组在各随访时间点均未观察到变化。舌下含服NTG后，两组随访期间FBF和LBF的变化相似。这些结果表明，长期口服沙格雷酯可改善PAD患者的血管功能。
Peripheral arterial disease (PAD) is 1 of the major manifestations of atherosclerosis. PAD is associated with endothelial dysfunction. Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, has been widely used as an anti-platelet agent for the treatment of PAD. There is no information on whether endothelial function is improved after initiation of sarpogrelate treatment in patients with PAD. The purpose of this study was to evaluate the effects of sarpogrelate on endothelial function in patients with PAD. We divided PAD patients into 2 groups: those treated with sarpogrelate at a dose of 100 mg 3 times per day orally for 12 weeks (sarpogrelate group, n = 10), and those who remained on conventional therapy (control group, n = 11). Forearm blood flow (FBF) and leg blood flow (LBF) responses to reactive hyperemia (RH) and sublingual administration of nitroglycerin (NTG) were measured using strain-gauge plethysmography. After 12 weeks of sarpogrelate administration, FBF and LBF responses during RE showed significant increases from 13.2 +/- 1.7 to 18.1 +/- 2.2 mL/min per 100 mL tissue (P < 0.01) and from 8.2 +/- 0.9 to 14.2 +/- 2.1 mL/min per 100 mL tissue (P < 0.05), respectively. Sarpogrelate-induced augmentation of FBF and LBF responses to RH was maintained at 24 weeks. No change was observed in the control group at each follow-up time point. The changes in FBF and LBF after sublingual NTG were similar during follow-up periods in the 2 groups. These findings suggest that long-term oral administration of sarpogrelate improves vascular function in patients with PAD.